Partner Headlines - TEVA

  1. Notable Hedge Funds Disclose Additions And Reductions To Holdings

    Benzinga
  2. Jana Partners LLC Files its 13F

    Benzinga
  3. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  4. Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

    IBD
  5. Did George Soros Sell His Stake In Israeli Based SodaStream Due ...

    Benzinga
  6. 5 Drug Companies Profiting From Generics

    Benzinga
  7. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  8. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  9. George Soros Reveals His Largest Stake

    GuruFocus
  10. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  11. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  12. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps ...

    GuruFocus
  13. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  14. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  15. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  16. Top 4 Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  17. Diamond Hill Capital Comments on Teva Pharmaceutical Industries ...

    GuruFocus
  18. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  19. Teva Pharmaceutical

    IBD
  20. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  21. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  22. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  23. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  24. Teva to buy Labrys Biologics

    IBD
  25. Chicago sues painkiller firms

    IBD
  26. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  27. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  28. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  29. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  30. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  31. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  32. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries ...

    Benzinga
  33. Teva EPS tops; rivals seen?

    IBD
  34. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  35. Earnings Scheduled For May 1, 2014

    Benzinga
  36. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  37. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  38. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  39. Morning Market Losers

    Benzinga
  40. Benzinga's Top #PreMarket Losers

    Benzinga
  41. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase ...

    Benzinga
  42. Nasdaq Could Be in for a Bounce

    FoxBusiness
  43. Actavis got a Pfizer

    IBD
  44. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received ...

    Benzinga
  45. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  46. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  47. Teva Announces First Approval and Launch of Generic Lovaza® Capsules ...

    Benzinga
  48. Market Wrap For April 7: Bears In Complete Control As Markets ...

    Benzinga
  49. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  50. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support ...

    Benzinga
  51. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  52. Market Wrap For March 28: Markets Still Positive Despite Giving ...

    Benzinga
  53. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  54. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  55. Forest Laboratories' Recovery

    GuruFocus
  56. Should You Buy Actavis?

    GuruFocus
  57. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  58. UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

    Benzinga
  59. UPDATE: Morgan Stanley Upgrades Teva Pharmaceutical Industries ...

    Benzinga
  60. Benzinga's Top Upgrades

    Benzinga
  61. US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

    Benzinga
  62. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  63. Pfizer Loses Bid to Hold Celebrex Exclusivity to '15

    FoxBusiness
  64. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  65. UPDATE: Barclays Upgrades Teva Pharmaceutical Industries Limited ...

    Benzinga
  66. Teva upgraded on drug launch

    IBD
  67. Teva Upgraded On Strong Launch Of Next-Gen Copaxone

    IBD
  68. Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA

    GuruFocus
  69. UPDATE: CRT Capital Initiates Coverage on OncoGenex

    Benzinga
  70. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  71. Insys Recovers From Stock Hit Tied To Fed Probe

    IBD
  72. Generic-Drug Makers Actavis, Mylan To Report Q4 Soon

    IBD
  73. #PreMarket Primer: Friday, February 7: Jobs Friday

    Benzinga
  74. Teva Pharmaceuticals A Giant In Generic Drugs

    IBD
  75. UPDATE: Teva Pharmaceutical Posts Upbeat Q4 Earnings

    Benzinga
  76. Earnings Scheduled For February 6, 2014

    Benzinga
  77. Market Wrap For January 29: Markets Lower on Fed Taper, Emerging ...

    Benzinga
  78. Stocks Hitting 52-Week Highs

    Benzinga
  79. Special Situations Alert: Details Behind Why I Bought PATH

    GuruFocus
  80. Teva, Active Biotech Say Remain Committed to Development of NERVENTRA

    Benzinga
  81. Benzinga's M&A Chatter for Tuesday January 21, 2014

    Benzinga
  82. NuPathe Terminates Agreement With Endo Pharma and Enters Into ...

    Benzinga
  83. US Stock Futures Up; Alcoa Earnings, Jobless Claims Data In Focus

    Benzinga
  84. Drug Mergers Queuing Up

    IBD
  85. Forest Buying Aptalis; Teva Bids For NuPathe Vs. Endo

    IBD
  86. Morning Market Movers

    Benzinga
  87. Benzinga's Top #PreMarket Gainers

    Benzinga
  88. Market Wrap For January 2: Markets Begin 2014 on Negative Note

    Benzinga
  89. Groups of Gurus Trade Ten-Year Low P/B Stocks - CLH, IMO and ...

    GuruFocus
  90. Market Wrap For December 27: Markets Quiet Before Weekend

    Benzinga
  91. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  92. Morning Market Movers

    Benzinga
  93. Benzinga's Top #PreMarket Gainers

    Benzinga
  94. Stocks To Watch For December 27, 2013

    Benzinga
  95. ANI Pharma Buys 31 Generic Drug Products from Teva for $12.5M ...

    Benzinga
  96. Teva Pharmaceuticals

    IBD
  97. Pfizer Settles Viagra Patent Litigation With Teva

    Benzinga
  98. Why Pfizer’s Expiring Viagra Patent Hurts Lilly Most

    YCharts
  99. Teva Pharmaceutical

    IBD
  100. Teva, Takeda Announce Agreement for Glatiramer Acetate for MSTreatment ...

    Benzinga
Trading Center